Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2012

Open Access 01-12-2012 | Short report

Higher mortality of patients on haemodialysis with pancreatic diabetes compared to type 2-diabetes

Authors: Gert Bodlaj, Georg Biesenbach

Published in: Diabetology & Metabolic Syndrome | Issue 1/2012

Login to get access

Abstract

In rare cases (1-8%) diabetic patients with end-stage renal disease (ESRD) suffer from diabetic nephropathy (dNP) due to pancreatic diabetes mellitus (PDM). Aim of this study was to investigate differences in the outcome of patients with PDM and those with type 2 diabetes.
In a retrospective study we evaluated 96 diabetic patients, who started hemodialysis (HD) in our dialysis centre (1997-2005). In 12 patients PMD was diagnosed, and 84 patients had type 2 diabetes. In both groups we compared vascular risk factors and prevalence of vascular diseases at the start of dialysis. We also evaluated incidence of malnutrition, and 5-year survival in both patient groups.
The vascular risk factors were similar in both patient groups, also the prevalence of vascular diseases at the initiation of HD was similar in both groups. In the patients with PDM the mean BMI (kg/m2) was lower (22 + 3 versus 25 + 3), and also their serum albumin was lower (2.7 + 0.3 versus 3.4 + 0.3 g/dl, p < 0.05). Four of these patients (33%) developed malnutrition (BMI < 18.5). In the patients with PDM the age adjusted 5-year survival was significantly lower (8% versus 27%, p < 0.05) than in the type 2 diabetic patients.
Conclusions in HD-treated patients with type 2 diabetes or PDM the prevalence of vascular diseases was not significantly different. The lower survival of PDM patients can be related to poor nutrition status.
Literature
1.
go back to reference Ito T, Olsuki M, Itoi T, Shimosegawa T, Funakosi A, Shiratory K, et al: Pancreatic Diabetes in follow-up survey of chronic pancreatitis in Japan. J Gastroenterol. 2007, 42: 291-297. 10.1007/s00535-006-1996-6.CrossRefPubMed Ito T, Olsuki M, Itoi T, Shimosegawa T, Funakosi A, Shiratory K, et al: Pancreatic Diabetes in follow-up survey of chronic pancreatitis in Japan. J Gastroenterol. 2007, 42: 291-297. 10.1007/s00535-006-1996-6.CrossRefPubMed
2.
go back to reference Sjoberg RJ, Kid GS: Pancreatic diabetes mellitus. Diabetes Care. 1989, 12: 715-724. 10.2337/diacare.12.10.715.CrossRefPubMed Sjoberg RJ, Kid GS: Pancreatic diabetes mellitus. Diabetes Care. 1989, 12: 715-724. 10.2337/diacare.12.10.715.CrossRefPubMed
3.
go back to reference Choudhuri G, Lakshmi CP, Goel A: Pancreatic diabetes. Trop Gastroenterol. 2009, 30: 71-75.PubMed Choudhuri G, Lakshmi CP, Goel A: Pancreatic diabetes. Trop Gastroenterol. 2009, 30: 71-75.PubMed
4.
go back to reference Hardt PD, Brendel MD, Kloer HU, Bretzel RG: Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed?. Diabetes Care. 2008, 31 (Suppl 2): S165-S169.CrossRefPubMed Hardt PD, Brendel MD, Kloer HU, Bretzel RG: Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed?. Diabetes Care. 2008, 31 (Suppl 2): S165-S169.CrossRefPubMed
5.
go back to reference Biesenbach G, Königsrainer A, Gross C, Margreiter R: Progression of macrovascular diseases is reduced in type 1 diabetic patients after more than 5 years successful combined pancreas-kidney transplantation in comparison to kidney transplantation alone. Transpl Int. 2005, 18: 1054-1060. 10.1111/j.1432-2277.2005.00182.x.CrossRefPubMed Biesenbach G, Königsrainer A, Gross C, Margreiter R: Progression of macrovascular diseases is reduced in type 1 diabetic patients after more than 5 years successful combined pancreas-kidney transplantation in comparison to kidney transplantation alone. Transpl Int. 2005, 18: 1054-1060. 10.1111/j.1432-2277.2005.00182.x.CrossRefPubMed
6.
go back to reference Chattopadhyay PS, Mukhopadhyay A, Chattopadhyay R, Gupta S: Macrovascular disease is not that uncommon in fibrocalculos pancreatic diabetes. Diabetes Care. 1995, 17: 462-463.CrossRef Chattopadhyay PS, Mukhopadhyay A, Chattopadhyay R, Gupta S: Macrovascular disease is not that uncommon in fibrocalculos pancreatic diabetes. Diabetes Care. 1995, 17: 462-463.CrossRef
7.
go back to reference Bergström J: Nutrition and mortality in hemodialysis. J Am Soc Nephrol. 1995, 6: 1329-1341.PubMed Bergström J: Nutrition and mortality in hemodialysis. J Am Soc Nephrol. 1995, 6: 1329-1341.PubMed
8.
go back to reference Weiner DE, Tighiouart H, Elsayed F, Griffith JL, Salem DN, Levey AS, Sarnak MJ: The relationship between nontraditional risk factors outcomes in individuals with stage 3 to 4 ckd. Am J Kidney Dis. 2008, 51: 212-223. 10.1053/j.ajkd.2007.10.035.PubMedCentralCrossRefPubMed Weiner DE, Tighiouart H, Elsayed F, Griffith JL, Salem DN, Levey AS, Sarnak MJ: The relationship between nontraditional risk factors outcomes in individuals with stage 3 to 4 ckd. Am J Kidney Dis. 2008, 51: 212-223. 10.1053/j.ajkd.2007.10.035.PubMedCentralCrossRefPubMed
Metadata
Title
Higher mortality of patients on haemodialysis with pancreatic diabetes compared to type 2-diabetes
Authors
Gert Bodlaj
Georg Biesenbach
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2012
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-4-9

Other articles of this Issue 1/2012

Diabetology & Metabolic Syndrome 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine